Rejected drug may protect against toxic substance common to Alzheimer's and Parkinson'... (two key proteins responsible for ALS-FTD...)

Rejected drug may protect against toxic substance common to Alzheimer's and Parkinson's diseases

Date:8/13/2012

two key proteins responsible for ALS-FTD, a spectrum of diseases that includes both Lou Gehrig's disease and frontotemporal dementia.

"The specificity of latrepirdine protection of yeast cells from alpha-synuclein poisoning was unexpected but highly specific and, we believe, occurs at doses of drug potentially relevant to the clinic," Dr. Petsko said.

"We believe that the U.S. latrepirdine trial failed because of a lack of understanding of how latrepirdine works," said Dr. Sano of the Mount Sinai Alzheimer's Disease Research Center. "Many of the patients in the Russian trial may have had a subtype of Alzheimer's disease that includes excess buildup of alpha-synuclein, making them more responsive to latrepirdine. We know that this occurs by chance in about one-third of Alzheimer's patients. The data indicating that latrepirdine both stimulates alpha-synuclein breakdown and protects cells from alpha-synuclein poisoning are highly intriguing."

Drs. Gandy and Yue are testing whether latrepirdine might be beneficial in treating or preventing disorders associated with high levels of alpha-synuclein such as Parkinson's disease, Lewy body dementia, and REM sleep disorder.

'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Rejected Alzheimers drug shows new potential
2. Gay Adults Rejected by Parents Have Worse Health, Study Finds
3. New Vaccine May Offer Protection From Deadly Nipah Virus
4. Protein that boosts longevity may protect against diabetes
5. Can herbal products provide sun protection?
6. NIH team describes protective role of skin microbiota
7. Researchers developing bioadhesive gel to protect women from HIV and HSV infections
8. Aspirin protects against Barretts esophagus
9. Vitamin D may protect against lung function impairment and decline in smokers
10. High Blood Pressure May Protect Some Frail Elderly: Study
11. Protecting the hearts of those waiting for kidney and liver transplants

Post Your Comments:

(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... the rights of victims injured by defective medical devices, is ... in the case of the Estate of Fred E. Taylor ... County (Port Orchard). A May 21, 2013, Bloomberg ... Surgical had acted like a “car dealership” in how it ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

(Date:5/21/2013)... results from SOURCE XT one of the largest, ... reported today at EuroPCR 2013 show good clinical outcomes ... success for all access approaches, valve sizes and delivery ... 2688 consecutively enrolled patients (mean age 81.5 years) undergoing ... centres in 17 countries between July 2010 and October ...

(Date:5/21/2013)... 2013 The federal judge overseeing the ... lawsuits in U.S. District Court, Northern District of ... request from Plaintiffs’ Counsel to conduct Ex Parte interviews ... 17th Order grants that request, and sets forth procedures ... Wright Medical Technology, Inc., Conserve Hip Implant Products Liability ...

(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...

Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2 Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2 Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3 Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2 Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3

[0] Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Post-approval TAVI registry shows high rates of device success at 1 year [0] Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation [0] Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island

... brain,s dopamine levels could point to more effective treatments ... -- Long-term changes in the brain,s dopamine-releasing machinery may ... say. , Dopamine is one of the brain,s major ... Bamford, of the University of Washington, Seattle, treated mice ...

... Skin Care and Frida,Kahlo Store are proud to announce the ... benefit of The Leukemia & Lymphoma Society. It,will take place ... Staten Island, New York, at 7:30 pm. This concert is ... with the solution,of health and social problems., The event ...

... leading global clinical,research organization, is pleased to announce that ... with CRO,s in Las Vegas, Nevada from April,14 to ... by,some of its executive team and employees. Chiltern will ... 2008 at 2:45 pm -- Track: Relationship Management ...

... to use iSEEK Medical Searchblade to optimize patient management ... ... 9 Physicians, nurses,physician assistants, pharmacists, and other clinicians searching for,medical ... Thanks to a new partnership between MedPage Today and iSEEK,the medical ...

... Peninsula Medical School, South West England, has found strong ... health of older people. , Two studies were conducted, ... Study of Ageing (ELSA). , The first study ... lived in urban areas across England. The study found ...

... April 9, 2008 Reflecting the,growing concern over ... in being able to afford a comfortable retirement,decreased ... in the 18 years of the,Retirement Confidence Survey(R)(RCS), ... of workers very confident about having enough money ...

Cached Medicine News:Health News:Researchers Define Mechanism of Methamphetamine Addiction 2 Health News:Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008. 2 Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 2 Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 3 Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 4 Health News:Your neighborhood can affect your health 2 Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 2 Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 3 Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 4

Researchers Define Mechanism of Methamphetamine Addiction Frida Kahlo - Passion for Life CONCERT GALA 2008 Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008.MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care Your neighborhood can affect your health 18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns

(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...

(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ... Summary ...

Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4

[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...

... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009. Gross profit was ...

Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7 Transgenomic Reports Fourth Quarter Financial Results 2 Transgenomic Reports Fourth Quarter Financial Results 3 Transgenomic Reports Fourth Quarter Financial Results 4 Transgenomic Reports Fourth Quarter Financial Results 5 Transgenomic Reports Fourth Quarter Financial Results 6 Transgenomic Reports Fourth Quarter Financial Results 7

Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer Transgenomic Reports Fourth Quarter Financial Results

Inquire...

Remote Blower With Bag-In/Bag-Out Option...

Class II Type B2 Biological Safety Cabinet...

Class II Type A2 Biological Safety Cabinet...

Medicine Products:

Benchtop Laminar Hood (Universal Hood)Remote Blower With Bag-In/Bag-Out Option Class II Type B2 Biological Safety Cabinet Class II Type A2 Biological Safety Cabinet